Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- First-line ATTR-CM treatment starts with subtype confirmation rather than selection of a specific therapy.
- Transthyretin-directed therapy and supportive heart failure care do different jobs, and both matter.
- Approved transthyretin stabilizers are indicated to reduce cardiovascular mortality and hospitalization, cited at indication level rather than compared.
- Treatment continuity following initiation is an integral component of first-line care.
Why First-Line Care Starts with Subtype Confirmation
First-line therapy in ATTR-CM begins with confirming that the patient is an appropriate candidate for transthyretin-directed therapy. Monoclonal protein exclusion, cardiac phenotype assessment, and hereditary-versus-wild-type clarification all determine whether long-term disease-directed therapy is appropriate in the first place. Accordingly, first-line treatment should follow the structured diagnostic approach described in the ATTR-CM treatment landscape before any treatment is initiated.
What Transthyretin-Directed Therapy and Supportive Care Each Do
Once that pathway is secure, transthyretin-directed therapy and supportive cardiac management have complementary roles. Disease-directed therapy aims to slow further amyloid deposition. Approved transthyretin stabilizers are indicated to reduce cardiovascular mortality and cardiovascular-related hospitalization. Supportive heart failure management, including diuretic therapy and other symptomatic measures, remains essential for ongoing symptom control. Neither approach replaces the other, which is why first-line care is targeted therapy plus supportive management.
Why Continuity Is Part of First-Line Care
An important component of first-line care is long-term treatment continuity. Real-world persistence experience makes clear that first-line care isn’t complete once therapy is prescribed: follow-up, adherence, refill continuity, and specialty coordination all influence whether an appropriate treatment decision continues to provide sustained clinical benefit over time. Establishing long-term treatment continuity is part of the first decision, not a later one, and it sets up second-line care if escalation is ever needed.
Clinical Decision Point
First-line therapy in ATTR-CM involves a structured sequence of clinical decisions rather than simply initiating treatment. Confirm the subtype and exclude amyloid light chain (AL) amyloidosis, match approved transthyretin-directed therapy to the patient within its label, run supportive heart failure care alongside it, and build the follow-up that keeps treatment continuous. The effectiveness of first-line therapy should be assessed over the clinical trajectory it aims to modify, not simply by the initiation of treatment.
Frequently Asked Questions
Where does first-line ATTR-CM treatment actually start?
It starts with subtype confirmation—excluding monoclonal disease, assessing the cardiac phenotype, and clarifying hereditary versus wild-type disease—before disease-directed therapy is chosen.
Do transthyretin-directed therapy and supportive care serve the same role?
No. Disease-directed therapy aims to slow further amyloid-related injury, while diuretic-centered heart failure care manages symptoms. Both run together in first-line care.
Is starting the drug the end of first-line care?
No. Follow-up, adherence, refill continuity, and specialty coordination determine whether a sound first decision continues to provide sustained clinical benefit, so continuity is part of first-line care.
Is first-line care a comparison between specific agents?
Not here. The emphasis is on the treatment sequence—confirm, treat within label, and protect continuity—rather than ranking approved stabilizers against one another.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- VYNDAQEL and VYNDAMAX prescribing information. U.S. Food and Drug Administration
- ATTRUBY (acoramidis) prescribing information. U.S. Food and Drug Administration
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. PubMed
- Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. Journal of American College of Cardiology
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.